Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Cash & Equivalents (2016 - 2025)

Heron Therapeutics' Cash & Equivalents history spans 14 years, with the latest figure at $11.6 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 510.53% year-over-year to $11.6 million; the TTM value through Dec 2025 reached $11.6 million, up 510.53%, while the annual FY2025 figure was $11.6 million, 510.53% up from the prior year.
  • Cash & Equivalents reached $11.6 million in Q4 2025 per HRTX's latest filing, down from $16.9 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $191.2 million in Q2 2021 to a low of $1.5 million in Q4 2022.
  • Average Cash & Equivalents over 5 years is $35.8 million, with a median of $16.7 million recorded in 2025.
  • Peak YoY movement for Cash & Equivalents: skyrocketed 2415.43% in 2021, then plummeted 98.34% in 2022.
  • A 5-year view of Cash & Equivalents shows it stood at $90.5 million in 2021, then tumbled by 98.34% to $1.5 million in 2022, then skyrocketed by 1811.8% to $28.7 million in 2023, then crashed by 93.37% to $1.9 million in 2024, then soared by 510.53% to $11.6 million in 2025.
  • Per Business Quant, the three most recent readings for HRTX's Cash & Equivalents are $11.6 million (Q4 2025), $16.9 million (Q3 2025), and $16.5 million (Q2 2025).